-
Infusion-related events during natalizumab: No need for post-infusion monitoring
Loonstra, F. C., van Rossum, J. A., van Kempen, Z. L. E., Rispens, T., Uitdehaag, B. M. J. & Killestein, J., 1 Oct 2020, In: Multiple sclerosis (Houndmills, Basingstoke, England). 26, 12, p. 1590-1593 4 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation
van Kempen, Z. L. E., van Rossum, J. A., Doesburg, D., Claessen, I., de Vries, A., ten Brinke, A., van Oosten, B. W., Rispens, T. & Killestein, J., 1 Jul 2019, In: Journal of neurology. 266, 7, p. 1804-1805 2 p.Research output: Contribution to journal › Comment/Letter to the editor* › Academic
-
Abnormalities and erythroblasts in peripheral blood of multiple sclerosis patients treated with natalizumab
van Rossum, J. A., van Kempen, Z. L. E., Schilder, L., Lissenberg-Witte, B. I., Uitdehaag, B. & Killestein, J., 2019, In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 36, 101382.Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
